- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Rheumatoid arthritis Psoriatic arthritis
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 503KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 140KB)
Tofacitinib – March 2024
Tofacitinib: Tablet (modified release) 11 mg; Xeljanz® XR
Last updated
30 May 2025